Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes

Effectiveness and Safety of Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes: a Retrospective, Observational Study

NCT07415226•Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

View on ClinicalTrials.gov

Summary

To assess the real-world impact of glucose-lowering drugs (GLDs) as an adjunct to insulin in Chinese patients with type 1 diabetes (T1DM). Does glucose-lowering drugs (GLDs) as an adjunct to insulin improve clinical outcomes in Chinese patients with type 1 diabetes (T1DM) when used long-term in real-world practice?

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The research group consists of T1DM patients who first used oral hypoglycemic drugs from January 2013 to June 2024 and had a glycated hemoglobin level of \>= 7%; The control group consisted of T1DM patients who maintained only insulin treatment regimen and had glycated hemoglobin \>= 7%;
•2. Age \>= 18 years old;
•3. At least one recorded HbA1c value before the start of treatment;
•4. Maintain medication regimen as needed from baseline to at least 3 months;
•5. Record the first glycated hemoglobin value after treatment.

Exclusion Criteria

•1. The patient had already used hypoglycemic drugs as an adjunct to insulin therapy before admission;
•2. DKA、 Serious infection, perioperative status, severe trauma, pregnancy, patient's past or current involvement in interventional clinical research；
•3. The standard for determining stress hyperglycemia by the supervising physician;
•4. Patients who have no medication records or have not followed the treatment plan formulated by the doctor.

Key Dates

Start Date

May 1, 2026

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2027

Last Updated

February 17, 2026

Enrollment

500

ESTIMATED participants

Conditions

Type 1 Diabetes Mellitus

Interventions

GLD+insulin group

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

NCT06390371

Type 1 Diabetes Mellitus

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

The Effects of Fluoxetine and/or DHEA

Fake Carbs Practice With AID System - MiniMed 780G in Children and Adolescents With T1D.

The COCCOS Study: a Transition Program for Young Persons With Chronic Conditions

Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy